LXEO

Insider Trades

Name	Value	Action	Price	Current Price
Townsend Richard NolanDirector, Officer: Chief Executive Officer $17k3.3k shares SellMay 18, 2026 $5.06 --
Otero Jose ManuelChief Operating Officer $6.6k1.3k shares SellMay 18, 2026 $5.07 --
Townsend Richard NolanDirector, Officer: Chief Executive Officer $313k55k shares SellApr 6, 2026 $5.69 --
Townsend Richard NolanDirector, Officer: Chief Executive Officer $65k10.2k shares SellFeb 18, 2026 $6.38 --
Otero Jose ManuelChief Operating Officer $19k3k shares SellFeb 18, 2026 $6.40 --
See Tai SandiChief Development Officer $3.6k386 shares SellNov 18, 2025 $9.27 --

News

globenewswire.comLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxiaglobenewswire.comJun 17

seekingalpha.comLexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcriptseekingalpha.comJun 15

benzinga.comWhy Is Lexeo Therapeutics Stock Gaining Monday?benzinga.comJun 15

globenewswire.comLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxiaglobenewswire.comJun 15

globenewswire.comLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conferenceglobenewswire.comMay 19

Trade LXEO

About Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

CEO: R. Nolan Townsend
IPO Date: Nov 3, 2023

Market Data

Open: $4.99
High: $5.34
Low: $4.92
Volume: 1.1M
Avg Volume: 860.3K
52W High: $10.99
52W Low: $3.60

Valuation

Market Cap: $387M
Enterprise Value: $323M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-99M
Revenue: $0
Net Income: $-100M
Cash: $63M
Debt: $7.9M

Events

EarningsAug 13

EPS est. -0.31